Steroid News and Research

RSS

Corticosteroids may decrease occurrence of hospital-acquired pneumonia in ICU patients

Patients admitted to a hospital with major trauma and treated with the steroid hydrocortisone were less likely to be diagnosed with hospital-acquired pneumonia than patients who received placebo, according to a study in the March 23/30 issue of JAMA.

23 Mar 2011

New drug for Lupus approved

A new drug for lupus has won U.S. approval. The drug, Benlysta from Human Genome Sciences Inc., is administered once a month intravenously.

12 Mar 2011

Research: CREBBP mutation may help cancer resist steroid treatment, fuel ALL's return

Despite dramatically improved survival rates for childhood acute lymphoblastic leukemia, relapse remains a leading cause of death from the disease. Work led by St. Jude Children's Research Hospital investigators identified mutations in a gene named CREBBP that may help the cancer resist steroid treatment and fuel ALL's return.

10 Mar 2011

Human Genome Sciences receives FDA approval for Benlysta to treat lupus

The U.S. Food and Drug Administration today approved Benlysta to treat patients with active, autoantibody-positive lupus who are receiving standard therapy, including corticosteroids, antimalarials, immunosuppressives, and nonsteroidal anti-inflammatory drugs.

9 Mar 2011

Vertos reports long-term safety and efficacy of mild in patients with LSS

Medical device company Vertos Medical Inc. has announced the release of clinical study data demonstrating the long-term safety and efficacy of mild as well as its superior durability over epidural steroid injections for treating lumbar spinal stenosis.

8 Mar 2011

5a-reductase inhibitors for male health problems can affect sexual health

A new study published in The Journal of Sexual Medicine reveals that, for the first time, 5a-reductase inhibitors commonly used to treat urinary problems in patients with benign prostatic hyperplasia (BPH) and found in popular medications to treat hair loss, can produce, persistent erectile dysfunction (ED), depression and loss of libido, even after the medication has been discontinued.

7 Mar 2011

Galderma, Astrazeneca collaborate to develop new compounds for dermatological disorders

AstraZeneca and Galderma Pharma S.A., a global speciality pharmaceutical company focused on dermatology, today announced they have entered into a R&D collaboration to develop new treatments for dermatological conditions including psoriasis, acne and atopic dermatitis which significantly affect the health and quality of life for millions of people worldwide.

7 Mar 2011

FDA approves Forest Labs' Daliresp to treat COPD

Forest Laboratories, Inc. announced today that Daliresp was approved by the U.S. Food and Drug Administration as a treatment to reduce the risk of chronic obstructive pulmonary disease exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

1 Mar 2011

Preliminary top-line results from cariprazine 8-week Phase II trial against major depressive disorder

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced preliminary top-line results from an 8-week Phase II clinical trial of the novel, investigational antipsychotic agent cariprazine as adjunctive therapy in major depressive disorder.

28 Feb 2011

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.

28 Feb 2011

Steroid administration may impact immune system in children with asthma

Children experiencing an asthma attack who are treated with a short burst of oral steroids may have a transient depression of immune response according to a new study led by Universit- de Montr-al.

24 Feb 2011

Boys get greater rush and more energy from caffeine than girls

Results of a double-blind, placebo-controlled, dose-response study of the response of youth to caffeine found that, in general, boys get a greater rush and more energy from caffeine than girls.

18 Feb 2011

Skeleton regulates fertility in males, but not females

Researchers at Columbia University Medical Center have discovered that the skeleton acts as a regulator of fertility in male mice through a hormone released by bone, known as osteocalcin.

17 Feb 2011

Astellas' Protopic receives Health Canada approval for prevention of eczema flares

Astellas Pharma Canada, Inc. has announced that it has received approval from Health Canada for a new indication for its topical eczema therapy, Protopic® (tacrolimus ointment 0.03% and 0.1%). The new indication means that tacrolimus ointment can be prescribed for maintenance therapy to prevent flares and prolong flare free intervals in patients with moderate to severe atopic dermatitis (commonly called eczema).

17 Feb 2011

New study confirms effectiveness of inhaled epinephrine to treat croup

For more than 30 years, pediatricians have treated children who have croup with inhaled epinephrine to relieve their symptoms quickly. Now, a new review confirms the value of this approach to treat this common respiratory illness, which sometimes turns serious and - in rare instances - can prove fatal.

16 Feb 2011

State court jury rules in favor of Merck in FOSAMAX trial

Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.

15 Feb 2011

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

Harbor BioSciences, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced it is closing the clinical sites of its U.S.-based Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

7 Feb 2011

Vascular birthmarks can cause concern for parents: Dermatologists

Vascular birthmarks, which occur in nearly 10 percent of all infants at birth or within the first few weeks of life, can cause concern for parents particularly if they are large or in a cosmetically important area. The decision to treat a birthmark is one that parents should make with a dermatologist, who can determine the type of birthmark and whether or not it poses any potential risks in the future.

5 Feb 2011

Dermatologists offer preventative tips to minimize pesky skin problems caused by plants

What may start as a seemingly harmless day of gardening or yard work can quickly take a turn for the worse when common plants make their mark on the skin, causing a host of mild to even severe skin reactions. That is why dermatologists are arming outdoor enthusiasts with preventative tips to keep these perils of the great outdoors at arm's length.

4 Feb 2011

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

Harbor BioSciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced publication of newly discovered anti-inflammatory steroids naturally present in humans.

2 Feb 2011